Intellectual Property India Publishes Patent Application for Xylanase-Responsive Nanoplatform For Oral Deucravacitinib And Iron-Gallate Nanozyme Therapy In Inflammatory Bowel Disease

MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202611078997 A) filed by Noida Institute Of Engineering And Technology Niet on June 26, 2026, for Xylanase-Responsive Nanoplatform For Oral Deucravacitinib And Iron-Gallate Nanozyme Therapy In Inflammatory Bowel Disease.

Inventors include Kajal; and Archna Singh.

The application for the patent was published on August 07, 2026, under issue no. 32/2026.

Abstract: The present invention discloses a xylanase-responsive oral nanoplatform (D-FeGA@cHX) for targeted inflammatory bowel disease treatment. A coordination-driven nanozyme (D-FeGA) is synthesized by coordinating deucravacitinib, a selective TYK2 inhibitor, with ferric ions and gallic acid, exhibit...